AzTrials
AzTrials

PainNCT01275911

Non-opioid Analgesia for Fast-track Surgery

A study testing Esmolol and Remifentanil in people with Pain, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In this randomized observer-blinded trial the analgesic efficacy of intravenous esmolol, as alternative to intraoperative opioids, is tested in patients undergoing laparoscopic prostatectomy and upper gastrointestinal surgery (such as Nissen fundoplication). Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Pain
What is being tested?
Esmolol and Remifentanil
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteCanada
Study dates
Jan 2009to Aug 2010
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with prostate cancer undergoing laparoscopic prostatectomy
  • Patients with gastro-esophageal reflux undergoing upper abdominal surgery (Nissen funduplication)

Who cannot join

  • Age <18 yr or > 85 yr
  • ASA physical status 3 and greater
  • History of hepatic failure (Child \& Pug A-C)
  • Renal failure (creatinine outside the normal range)
  • Cardiac failure (NYHA I-IV)
  • Organ transplant
Show all 14Show fewer
  • Diabetes mellitus type 1 and 2
  • Morbid obesity (BMI > 40)
  • Chronic use of opioids and beta-blockers
  • Severe mental impairment
  • History of allergic reactions to all the medications used in the study or inability to understand pain assessment.
  • Asthma or Reactive airway disease
  • Patient with known or suspected peritoneal adhesion
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Montreal General Hospital, McGill University Health Centre

    Montreal, Quebec, H3G1A4

Other trials in Canada

About this study

Official title: Fast-track Laparoscopic Surgery. The Effect of Anesthetic Technique

In this randomized observer-blinded trial the analgesic efficacy of intravenous esmolol, as alternative to intraoperative opioids, is tested in patients undergoing laparoscopic prostatectomy and upper gastrointestinal surgery (such as Nissen fundoplication). The purpose of this study is to determine whether intravenous esmolol improves postoperative analgesia and accelerate the surgical recovery. We hypothesize that patients receiving intravenous esmolol will consume less analgesic in the postoperative period, will have less opioid-related side effects and will recover their functional status faster then patients receiving intravenous esmolol.

Patients will be stratified according to the type of surgical procedure in 2 arms: 40 patients with prostate cancer and undergoing elective laparoscopic prostatectomy, and 40 patients with gastro-esophageal reflux undergoing upper gastrointestinal surgery (Nissen funduplication) will be enrolled.

Patients will receive total intravenous anesthesia with propofol and esmolol (Esmolol group, n=20 in each arm) or propofol and remifentanil (Remifentanil Group, n=20 in each arm).

Read the detailed description

Outcomes:

  1. Primary: The amount of fentanyl needed in PACU and the amount of PCA morphine used during the first 24 postoperative hours.
  2. Secondary: intensity of postoperative pain (visual analogue scale,VAS), opioids side effects, length of stay in PACU and in the hospital, short-term SF-36 questionnaire, CHAMPS questionnaire, and the 2 and 6 minutes walking tests.

Methodology:

In each arm patients will be assigned by computer generated random letters to two groups:

The Esmolol group: patients will receive no opioids but will receive esmolol at induction and as a continuous infusion during the surgery.

The Remifentanil group: patients will receive remifentanil as sole opioid during induction of anesthesia as a continuous infusion during the surgery.

During the preoperative assessment patients will be asked to fill out the CHAMPS and the Short-term SF-36 questionnaires. The 2 and 6 minutes walking tests will be also administered

On arrival in the operating room, routine monitors will be applied for recording heart rate, systolic blood pressure, and oxygen saturation. In addition, the electroencephalographic bispectral index (BIS) value was obtained using a single channel sensor in a frontal temporal area. The BIS is a standard monitor of depth of anesthesia and measures cortical activation. It has been found to be well correlated to electroencephalogram. After obtaining baseline values, midazolam 1-2mg IV will be administered for pre-medication. Anesthesia will be subsequently induced with Propofol 2-2.5 mg/kg, Rocuronium 0.45-0.9 mg/kg.

The Esmolol group will receive 1.0 mg/kg of esmolol and the Remifentanil group 1.0 mcg/kg of remifentanil for induction of anesthesia. After direct laryngoscopy and tracheal intubation will have been performed, anesthesia will be maintained with a continuous infusion of propofol 80-250 mcg/kg/min to maintain a "targeted" BIS value of 50 or less (BIS below 60 signifies the patient is asleep and unaware, 90 and over signifies intraoperative wakefulness). Patients will receive either esmolol infusion of 5-15 mcg/kg/min or remifentanil infusion of 0.025-0.25mcg/kg/min (in Esmolol group or in the Remifentanil group respectively) titrated to maintain HR within 25% of the pre-induction baseline value with targeted HR in between 55-90. Furthermore, the patients will also receive IV fluid at 6 ml/kg. All patients will be mechanically ventilated to maintain the end-tidal carbon dioxide (CO2) concentration in the range of 36-44 mm Hg and will receive toward the end of surgery Ketorolac 30mg IV, Droperidol 0.625mg IV and neuromuscular reversal if needed. Propofol will be discontinued after the last skin suture and the remifentanil or esmolol infusions will be stopped. After closure 10cc of bupivacaine 0.25% with epinephrine 1:200.000 will be infiltrated in the surgical ports. Nurses in the PACU will be informed that patients are taking part of the study but will not be aware of the hypothesis and will provide patients with standard care. Patients will have access in PACU to Fentanyl 25mcg IV q5min and to Ondansetron 2-8mg IV prn (standard medications used in this institution). Patients will receive PCA morphine for 24-48 h with tylenol 650mg PO q4h and naproxen 500mg or celebrex 200 mg PO bid.

Heart rate, blood pressure, BIS and oxygen saturation will be recorded at baseline, induction of anesthesia, tracheal intubation, skin incision, and subsequently at 5 min intervals until the end of surgery. Patients will be extubated in the operating room. They will then be transported to the post anesthesia care unit (PACU).

Assessment:

Recovery time will be assessed by a blinded observer (research fellow) unaware of the study hypothesis from the time the study drugs are discontinued. Times to awakening (opening eyes on verbal command), and orientation to person, date and place will be recorded, whereas the time to home readiness will be evaluated using standardized discharge criteria as described by White-Song17 at 30 min intervals. The score maximum of 12 out of 14 allows the patients to be discharged to the surgical ward from the PACU. Pain will be assessed every 15 minutes using (visual analog scale) (VAS)18 (0-10 cm) at rest, on movements and on coughing by the recovery nurse. Postoperative side effects (nausea, vomiting, pain), requirement for analgesics and antiemetics therapy (morphine and zofran respectively), as well as patient satisfaction will be assessed on discharge from PACU and 24-48 hrs after the procedure.

Conditions
Pain
Being tested
Esmolol, Remifentanil
Medical subject headings
Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EsmololDrug

    Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min

  • RemifentanilDrug

    At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min

Study groups in NCT01275911
Study groupRoleWhat they receive
EsmololExperimentalNot described
Receives: Drug: Esmolol
RemifentanilActive comparatorNot described
Receives: Drug: Remifentanil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Amount of postoperative opioid consumption

    Measured: End of surgery- 24hr from the end of surgery

Secondary outcomes (8)
  1. Postoperative pain intensity

    Measured: every 24 hr from the end of surgery

  2. Incidence of opioids side-effects

    Measured: during the duration of hospital stay

  3. Length of stay in the PACU

    Measured: time spent in the recovery room

  4. Length of stay in the hospital

    Measured: duration of hospitalization after the surgery

  5. CHAMPS questionnaire

    Measured: preoperative, at 3 and 8 weeks after the surgery

  6. short-term SF-36

    Measured: preoperative, at 3 and 8 weeks after the surgery

  7. 2 minutes walking test

    Measured: preoperative, at 4 weeks after the surgery

  8. 6 minutes walking test

    Measured: preoperative, at 4 weeks after the surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2011 (estimated)
  2. Study startJan 2009
  3. Primary completionJul 2010
  4. Study completionAug 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01275911
Sponsor's protocol ID
GEN#08-22
Status last verified
Mar 2013
First submitted
12 Jan 2011
Last updated
27 Mar 2013
Results posted
No
Data monitoring committee
Yes

Publications

  • Collard V, Mistraletti G, Taqi A, Asenjo JF, Feldman LS, Fried GM, Carli F. Intraoperative esmolol infusion in the absence of opioids spares postoperative fentanyl in patients undergoing ambulatory laparoscopic cholecystectomy. Anesth Analg. 2007 Nov;105(5):1255-62, table of contents. doi: 10.1213/01.ane.0000282822.07437.02.

    PubMed 17959952
  • Coloma M, Chiu JW, White PF, Armbruster SC. The use of esmolol as an alternative to remifentanil during desflurane anesthesia for fast-track outpatient gynecologic laparoscopic surgery. Anesth Analg. 2001 Feb;92(2):352-7. doi: 10.1097/00000539-200102000-00014.

    PubMed 11159231
  • Johansen JW, Schneider G, Windsor AM, Sebel PS. Esmolol potentiates reduction of minimum alveolar isoflurane concentration by alfentanil. Anesth Analg. 1998 Sep;87(3):671-6. doi: 10.1097/00000539-199809000-00034.

    PubMed 9728851
  • White PF, Wang B, Tang J, Wender RH, Naruse R, Sloninsky A. The effect of intraoperative use of esmolol and nicardipine on recovery after ambulatory surgery. Anesth Analg. 2003 Dec;97(6):1633-1638. doi: 10.1213/01.ANE.0000085296.07006.BA.

    PubMed 14633533
  • Chia YY, Chan MH, Ko NH, Liu K. Role of beta-blockade in anaesthesia and postoperative pain management after hysterectomy. Br J Anaesth. 2004 Dec;93(6):799-805. doi: 10.1093/bja/aeh268. Epub 2004 Sep 17.

    PubMed 15377583
  • Erdil F, Demirbilek S, Begec Z, Ozturk E, But A, Ozcan Ersoy M. The effect of esmolol on the QTc interval during induction of anaesthesia in patients with coronary artery disease. Anaesthesia. 2009 Mar;64(3):246-50. doi: 10.1111/j.1365-2044.2008.05754.x.

    PubMed 19302635
  • Smith I, Van Hemelrijck J, White PF. Efficacy of esmolol versus alfentanil as a supplement to propofol-nitrous oxide anesthesia. Anesth Analg. 1991 Nov;73(5):540-6.

    PubMed 1683182
  • White PF. The role of non-opioid analgesic techniques in the management of pain after ambulatory surgery. Anesth Analg. 2002 Mar;94(3):577-85. doi: 10.1097/00000539-200203000-00019. No abstract available.

    PubMed 11867379

Questions about this trial

What is this clinical trial studying?

A study testing Esmolol and Remifentanil in people with Pain, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Amount of postoperative opioid consumption (time frame: End of surgery- 24hr from the end of surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01275911, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in